StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ALX Oncology's operating cash flow for the twelve months ending Jun 30, 2026 was -$70.78M. For fiscal 2025 it was -$84.14M. The highest annual figure on record is -$13.19M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.14M–
FY2024Dec 31, 2024-$121.91M–
FY2023Dec 31, 2023-$130.36M–
FY2022Dec 31, 2022-$89.22M–
FY2021Dec 31, 2021-$68.10M–
FY2020Dec 31, 2020-$38.29M–
FY2019Dec 31, 2019-$14.25M–
FY2018Dec 31, 2018-$13.19M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.06M–
Q1 FY2026Mar 31, 2026-$18.65M–
Q4 FY2025Dec 31, 2025-$18.98M–
Q3 FY2025Sep 30, 2025-$17.09M–
Q2 FY2025Jun 30, 2025-$23.41M–
Q1 FY2025Mar 31, 2025-$24.66M–
Q4 FY2024Dec 31, 2024-$32.05M–
Q3 FY2024Sep 30, 2024-$25.38M–
Q2 FY2024Jun 30, 2024-$26.57M–
Q1 FY2024Mar 31, 2024-$37.92M–
Q4 FY2023Dec 31, 2023-$39.68M–
Q3 FY2023Sep 30, 2023-$31.16M–
Q2 FY2023Jun 30, 2023-$31.71M–
Q1 FY2023Mar 31, 2023-$27.82M–
Q4 FY2022Dec 31, 2022-$20.67M–
Q3 FY2022Sep 30, 2022-$30.88M–
Q2 FY2022Jun 30, 2022-$17.00M–
Q1 FY2022Mar 31, 2022-$20.67M–
Q4 FY2021Dec 31, 2021-$17.49M–
Q3 FY2021Sep 30, 2021-$24.86M–
Q2 FY2021Jun 30, 2021-$20.62M–
Q1 FY2021Mar 31, 2021-$5.14M–
Q4 FY2020Dec 31, 2020-$13.62M–
Q3 FY2020Sep 30, 2020-$9.55M–
Q2 FY2020Jun 30, 2020-$6.16M–
Q1 FY2020Mar 31, 2020-$8.96M–
Q4 FY2019Dec 31, 2019-$2.87M–
Q3 FY2019Sep 30, 2019-$3.19M–

More ALX Oncology figures

See a number that looks wrong?